The European medical cannabis market is still in its infancy, with much work to be done before patient access catches up to the levels seen in North America.
In order to best serve the medical cannabis patient population in Europe, operators need an understanding of who the patients are and why they rely on these medicines. Prohibition Partners has summarised the available data below, and provided more analysis in our recent European Cannabis Report.
Prohibition Partners has gathered data for European medical cannabis patients from national government agencies and independent research groups to investigate high-level statistics on patients being prescribed medical cannabis. One of the foremost sources of data in Europe is Project Twenty21, run by Drug Science in the UK, which is a patient registry that ‘aims to create the UK’s largest body of evidence for the effectiveness and tolerability of medical cannabis’ by facilitating patient access and subsequently publishing anonymised data.